OCA

Octagon Capital Advisors Portfolio holdings

AUM $456M
This Quarter Return
+21.36%
1 Year Return
+48.55%
3 Year Return
+560.4%
5 Year Return
–
10 Year Return
–
AUM
$456M
AUM Growth
+$456M
Cap. Flow
-$144M
Cap. Flow %
-31.52%
Top 10 Hldgs %
60.57%
Holding
36
New
2
Increased
7
Reduced
13
Closed
6

Top Buys

1
SPRY icon
ARS Pharmaceuticals
SPRY
$12.7M
2
KYMR icon
Kymera Therapeutics
KYMR
$11.6M
3
VRNA
Verona Pharma
VRNA
$11.3M
4
DBVT
DBV Technologies
DBVT
$9.31M
5
TSHA icon
Taysha Gene Therapies
TSHA
$4.37M

Top Sells

1
NUVB.WS icon
Nuvation Bio Inc. Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50
NUVB.WS
$53M
2
UNCY icon
Unicycive Therapeutics
UNCY
$42.9M
3
APLS icon
Apellis Pharmaceuticals
APLS
$20.6M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
$11.1M
5
SRRK icon
Scholar Rock
SRRK
$10.6M

Sector Composition

1 Healthcare 99.93%
Name Market Value Portfolio Weight Shares or Principal Shares
Change % 		Capital Flow
BBOT
26
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$778M
$2.66M 0.58%
250,000
– –
MAZE
27
Maze Therapeutics, Inc. Common Stock
MAZE
$689M
$2.18M 0.48%
177,667
-290,333
-62% -$3.56M
KLRS
28
Kalaris Therapeutics, Inc. Common Stock
KLRS
$82.1M
$961K 0.21%
360,000
-121,000
-25% -$323K
ERAS icon
29
Erasca
ERAS
$391M
$889K 0.2%
700,000
-4,436,795
-86% -$5.63M
NUVB.WS icon
30
Nuvation Bio Inc. Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50
NUVB.WS
$67.9M
$301K 0.07%
154,112
-27,176,688
-99% -$53M
CATX icon
31
Perspective Therapeutics
CATX
$249M
– –
-2,250,000
Closed -$4.79M
RGLS
32
DELISTED
Regulus Therapeutics
RGLS
– –
-4,637,076
Closed -$8.11M
SNDX icon
33
Syndax Pharmaceuticals
SNDX
$1.37B
– –
-904,000
Closed -$11.1M
SRRK icon
34
Scholar Rock
SRRK
$3.31B
– –
-329,000
Closed -$10.6M
VRDN icon
35
Viridian Therapeutics
VRDN
$1.58B
– –
-450,000
Closed -$6.07M
VSTM icon
36
Verastem
VSTM
$563M
– –
-1,720,000
Closed -$10.4M
1
2